Genetic origins of hyper-IgE syndrome

Current Allergy and Asthma Reports

Volumn 8, Issue 5, 2008, Pages 386-391

  Minegishi, Yoshiyuki ^a   Karasuyama, Hajime ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NONE

Author keywords

Atopic Dermatitis; Autosomal Dominant; Autosomal Recessive; Dental Abnormality; Hypomorphic Mutation

Indexed keywords

ALPHA INTERFERON; CYTOKINE; IMMUNOGLOBULIN E; INTERLEUKIN 17; JANUS KINASE; PROTEIN KINASE TYK2; STAT3 PROTEIN;

ANIMAL; ARTICLE; BLOOD; DERMATITIS; GENETICS; HUMAN; HYPER IGE SYNDROME; IMMUNOLOGY; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; DERMATITIS; HUMANS; IMMUNOGLOBULIN E; INTERFERON-ALPHA; INTERLEUKIN-17; JANUS KINASES; JOB'S SYNDROME; MICE; MICE, KNOCKOUT; MUTATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TYK2 KINASE;

EID: 55249087468     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-008-0075-x     Document Type: Article

References (56)

1. Minegishi Y, Karasuyama H: Hyperimmunoglobulin E syndrome and tyrosine kinase 2 deficiency. Curr Opin Allergy Clin Immunol 2007, 7:506–509. DOI: 10.1097/ACI.0b013e3282f1baea
2. Grimbacher B, Holland SM, Puck JM: Hyper-IgE syndromes. Immunol Rev 2005, 203:244–250. DOI: 10.1111/j.0105-2896.2005.00228.x
3. Grimbacher B, Holland SM, Gallin JI, et al.: Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. N Engl J Med 1999, 340:692–702. DOI: 10.1056/NEJM199903043400904
4. Freeman AF, Kleiner DE, Nadiminti H, et al.: Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol 2007, 119:1234–1240. DOI: 10.1016/j.jaci.2006.12.666
5. Renner ED, Puck JM, Holland SM, et al.: Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr 2004, 144:93–99. DOI: 10.1016/S0022-3476(03)00449-9
6. Ihle JN: Cytokine receptor signalling. Nature 1995, 377:591–594. DOI: 10.1038/377591a0
7. Liu KD, Gaffen SL, Goldsmith MA: JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 1998, 10:271–278. DOI: 10.1016/S0952-7915(98)80165-9
8. O’shea JJ, Gadina M, Schreiber RD: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002, 109(Suppl):S121–S131. DOI: 10.1016/S0092-8674(02)00701-8
9. Muller M, Briscoe J, Laxton C, et al.: The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and-gamma signal transduction. Nature 1993, 366:129–135. DOI: 10.1038/366129a0
10. Rodig SJ, Meraz MA, White JM, et al.: Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373–383. DOI: 10.1016/S0092-8674(00)81166-6
11. Neubauer H, Cumano A, Muller M, et al.: Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397–409. DOI: 10.1016/S0092-8674(00)81168-X
12. Parganas E, Wang D, Stravopodis D, et al.: Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93:385–395. DOI: 10.1016/S0092-8674(00)81167-8
13. Nosaka T, van Deursen JM, Tripp RA, et al.: Defective lymphoid development in mice lacking Jak3. Science 1995, 270:800–802. DOI: 10.1126/science.270.5237.800
14. Park SY, Saijo K, Takahashi T, et al.: Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995, 3:771–782. DOI: 10.1016/1074-7613(95)90066-7
15. Macchi P, Villa A, Giliani S, et al.: Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65–68. DOI: 10.1038/377065a0
16. Russell SM, Tayebi N, Nakajima H, et al.: Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995, 270:797–800. DOI: 10.1126/science.270.5237.797
17. Firmbach-Kraft I, Byers M, Shows T, et al.: Tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 1990, 5:1329–1336.
18. Velazquez L, Fellous M, Stark GR, Pellegrini S: A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992, 70:313–322. DOI: 10.1016/0092-8674(92)90105-L
19. Karaghiosoff M, Neubauer H, Lassnig C, et al.: Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000, 13:549–560. DOI: 10.1016/S1074-7613(00)00054-6
20. Shimoda K, Kato K, Aoki K, et al.: Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000, 13:561–571. DOI: 10.1016/S1074-7613(00)00055-8
21. Bacon CM, McVicar DW, Ortaldo JR, et al.: Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995, 181:399–404. DOI: 10.1084/jem.181.1.399
22. Stahl N, Boulton TG, Farruggella T, et al.: Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994, 263:92–95. DOI: 10.1126/science.8272873
23. Minegishi Y, Coustan-Smith E, Wang YH, et al.: Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med 1998, 187:71–77. DOI: 10.1084/jem.187.1.71
24. Minegishi Y, Rohrer J, Coustan-Smith E, et al.: An essential role for BLNK in human B cell development. Science 1999, 286:1954–1957. DOI: 10.1126/science.286.5446.1954
25. Conley ME, Rohrer J, Rapalus L, et al.: Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse. Immunol Rev 2000, 178:75–90. DOI: 10.1034/j.1600-065X.2000.17809.x
26. Akira S, Nishio Y, Inoue M, et al.: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77:63–71. DOI: 10.1016/0092-8674(94)90235-6
27. Zhong Z, Wen Z, Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95–98. DOI: 10.1126/science.8140422
28. Wegenka UM, Buschmann J, Lutticken C, et al.: Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 1993, 13:276–288.
29. Lutticken C, Wegenka UM, Yuan J, et al.: Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994, 263:89–92. DOI: 10.1126/science.8272872
30. Nakajima K, Yamanaka Y, Nakae K, et al.: A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996, 15:3651–3658.
31. Williams L, Bradley L, Smith A, Foxwell B: Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004, 172:567–576.
32. Minami M, Inoue M, Wei S, et al.: STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A 1996, 93:3963–3966. DOI: 10.1073/pnas.93.9.3963
33. Takeda K, Noguchi K, Shi W, et al.: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997, 94:3801–3804. DOI: 10.1073/pnas.94.8.3801
34. Akira S: Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000, 19:2607–2611. DOI: 10.1038/sj.onc.1203478
35. Kasprzycka M, Marzec M, Liu X, et al.: Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A 2006, 103:9964–9969. DOI: 10.1073/pnas.0603507103
36. Davis SD, Schaller J, Wedgwood RJ: Job’s syndrome. Recurrent, “cold,” staphylococcal abscesses. Lancet 1966, 1:1013–1015. DOI: 10.1016/S0140-6736(66)90119-X
37. Buckley RH, Wray BB, Belmaker EZ: Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 1972, 49:59–70.
38. Del Prete G, Tiri A, Maggi E, et al.: Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome. J Clin Invest 1989, 84:1830–1835. DOI: 10.1172/JCI114368
39. Borges WG, Augustine NH, Hill HR: Defective interleukin-12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome. J Pediatr 2000, 136:176–180. DOI: 10.1016/S0022-3476(00)70098-9
40. Chehimi J, Elder M, Greene J, et al.: Cytokine and chemokine dysregulation in hyper-IgE syndrome. Clin Immunol 2001, 100:49–56. DOI: 10.1006/clim.2001.5039
41. Wood PM, Fieschi C, Picard C, et al.: Inherited defects in the interferon-gamma receptor or interleukin-12 signalling pathways are not sufficient to cause allergic disease in children. Eur J Pediatr 2005, 164:741–747. DOI: 10.1007/s00431-005-1745-5
42. Minegishi Y, Saito M, Morio T, et al.: Human tyrosine kinase 2 deficiency reveals its requisute roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006, 25:745–755. DOI: 10.1016/j.immuni.2006.09.009
43. Casanova JL, Abel L: Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002, 20:581–620. DOI: 10.1146/annurev.immunol.20.081501.125851
44. Minegishi Y, Saito M, Tsuchiya S, et al.: Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058–1062. DOI: 10.1038/nature06096
45. Grimbacher B, Schaffer AA, Holland SM, et al.: Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 1999, 65:735–744. DOI: 10.1086/302547
46. Holland SM, DeLeo FR, Elloumi HZ, et al.: STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357:1608–1619. DOI: 10.1056/NEJMoa073687
47. Renner ED, Torgerson TR, Rylaarsdam S, et al.: STAT3 mutation in the original patient with Job’s syndrome. N Engl J Med 2007, 357:1667–1668. DOI: 10.1056/NEJMc076367
48. Dupuis S, Dargemont C, Fieschi C, et al.: Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001, 293:300–303. DOI: 10.1126/science.1061154
49. Itoh S, Udagawa N, Takahashi N, et al.: A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. Bone 2006, 39:505–512. DOI: 10.1016/j.bone.2006.02.074
50. Yang XO, Panopoulos AD, Nurieva R, et al.: STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007, 282:9358–9363. DOI: 10.1074/jbc.C600321200
51. Toy D, Kugler D, Wolfson M, et al.: Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006, 177:36–39.
52. Aujla SJ, Chan YR, Zheng M, et al.: IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. Nat Med 2008, 14:275–281. DOI: 10.1038/nm1710
53. Zheng Y, Valdez PA, Danilenko DM, et al.: Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008, 14:282–289. DOI: 10.1038/nm1720
54. Kreymborg K, Etzensperger R, Dumoutier L, et al.: IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007, 179:8098–8104.
55. Wolk K, Kunz S, Witte E, et al.: IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241–254. DOI: 10.1016/j.immuni.2004.07.007
56. Milner JD, Brenchley JM, Laurence A, et al.: Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773–776. DOI: 10.1038/nature06764